{"name":"Affiris AG","slug":"affiris-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AFFITOPE AD01","genericName":"AFFITOPE AD01","slug":"affitope-ad01","indication":"Other","status":"phase_1"},{"name":"AFFITOPE AD01 adjuvanted","genericName":"AFFITOPE AD01 adjuvanted","slug":"affitope-ad01-adjuvanted","indication":"Other","status":"phase_1"},{"name":"AFFITOPE AD03","genericName":"AFFITOPE AD03","slug":"affitope-ad03","indication":"Other","status":"phase_1"},{"name":"ATH03","genericName":"ATH03","slug":"ath03","indication":"Other","status":"phase_1"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AFFITOPE® PD01A","genericName":"AFFITOPE® PD01A","slug":"affitope-pd01a","indication":"Parkinson's disease","status":"phase_1"}]}],"pipeline":[{"name":"AFFITOPE AD01","genericName":"AFFITOPE AD01","slug":"affitope-ad01","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AFFITOPE AD01 adjuvanted","genericName":"AFFITOPE AD01 adjuvanted","slug":"affitope-ad01-adjuvanted","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AFFITOPE AD03","genericName":"AFFITOPE AD03","slug":"affitope-ad03","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AFFITOPE® PD01A","genericName":"AFFITOPE® PD01A","slug":"affitope-pd01a","phase":"phase_1","mechanism":"AFFITOPE® PD01A is designed to induce an immune response against alpha-synuclein, a protein implicated in Parkinson's disease.","indications":["Parkinson's disease"],"catalyst":""},{"name":"ATH03","genericName":"ATH03","slug":"ath03","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxQdzNUZFRCTVhoSUllbW1XakkxWEZseVhpUVpUMldwNkhMSGZSR0EtYlFZdTREMG5hVUpPWDRwMEJfNW94eU1JbzdXeUVubkl5MnZtUFZLWTMzME9kbW9yTnFkVWdtQjJLRjVBdWtxeHMyTDh6Rk5peXNDaHUxSWthampFTVdfbVowNExVUmFvMnpOYjlsVGs1MmpLbHlvbW56RmlBOE5zVnZzY2VVYnlrU2dST0k5RmVGTU9GdVI5eDBDd1lURE1vU2tBV1ZuR1lwUzNwanBWS29uNW5qZVVaVGtvT1VkdXVkU2swQlQxQVgtNWVkdk95UEVJUVRycDAzNk9mSjl0b1RZaXV1cGxzSlg1bUE3Q3FTWmVLVFgzWW9YQ2M5amNaeQ?oc=5","date":"2025-02-13","type":"trial","source":"GlobeNewswire","summary":"Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel - GlobeNewswire","headline":"Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_1":5},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}